.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
US Department of Justice
Dow
Merck
Healthtrust
Farmers Insurance
Moodys
Citi
AstraZeneca
McKinsey

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021402

« Back to Dashboard

NDA 021402 describes SYNTHROID, which is a drug marketed by Abbvie and is included in one NDA. It is available from eight suppliers. Additional details are available on the SYNTHROID profile page.

The generic ingredient in SYNTHROID is levothyroxine sodium. There are ten drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

Summary for 021402

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
Formulation / Manufacturing:see details

Pharmacology for NDA: 021402

Ingredient-typeThyroxine

Suppliers and Packaging for NDA: 021402

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SYNTHROID levothyroxine sodium TABLET;ORAL 021402 NDA AbbVie Inc. 0074-3727 0074-3727-71 4 BLISTER PACK in 1 CARTON (0074-3727-71) > 7 TABLET in 1 BLISTER PACK
SYNTHROID levothyroxine sodium TABLET;ORAL 021402 NDA AbbVie Inc. 0074-3727 0074-3727-90 90 TABLET in 1 BOTTLE (0074-3727-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Jul 24, 2002TE:AB1,AB2RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Jul 24, 2002TE:AB1,AB2RLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Jul 24, 2002TE:AB1,AB2RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chubb
AstraZeneca
Colorcon
Dow
Covington
QuintilesIMS
Moodys
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot